Abstract
These results identified a critical role of entrectinib in promoting nerve cell damage by downregulating the expression of THBS1 while also inhibiting PI3K-AKT and TGF-β signaling pathways. Our findings will provide potential therapeutic targets for CNS-related toxicities.
Introduction
Entrectinib is a potent tyrosine receptor kinase inhibitor (TRKi) designed to treat tumors harboring NTRK or ROS1 gene fusions. Its ability to cross the blood-brain barrier makes it highly effective against brain metastases. However, this same permeability is linked to significant central nervous system (CNS) toxicities, including cognitive impairment, dizziness, and peripheral neuropathy, affecting up to 45% of patients. This study investigates the molecular mechanisms underlying entrectinib-induced neurotoxicity to identify potential protective strategies that could mitigate side effects without compromising anti-cancer efficacy.
Methods
The researchers utilized a multi-layered approach using three distinct nerve cell models: rat (PC12), mouse (HT22), and human (SK-N-SH).
- Phenotypic Assays: Standard assays (CCK-8, colony formation, and EdU incorporation) measured cell viability and proliferation, while flow cytometry quantified apoptosis.
- Transcriptomics: RNA sequencing (RNA-seq) identified differentially expressed genes (DEGs) in entrectinib-treated cells.
- Bioinformatics: Tools like Gene Ontology (GO), KEGG pathway analysis, and Gene Set Enrichment Analysis (GSEA) mapped genetic changes to specific biological pathways.
- Validation & Rescue: Findings were validated through qRT-PCR and Western blotting. Crucially, rescue experiments were conducted by overexpressing the THBS1 gene to evaluate its protective potential.
Key Results
The study demonstrated that entrectinib induces dose-dependent toxicity across all tested cell lines. For instance, in HT22 cells, increasing concentrations of entrectinib significantly reduced cell viability, as shown by decreasing absorbance levels.
Key findings include:
- Dose-Dependent Toxicity: Half-maximal inhibitory concentrations (IC50) ranged from 2.3 to 4.3 μmol/L.
- Increased Apoptosis: Treatment boosted cell death rates from ~3% in controls to over 15% in treated groups.
- THBS1 as a Master Link: Thrombospondin-1 (THBS1) emerged as the critical gene downregulated by entrectinib across all three species. THBS1 is essential for axon regeneration and synapse formation.
- Signaling Shutdown: Suppression of THBS1 inadvertently deactivated the PI3K-AKT (survival) and TGF-β (growth/differentiation) pathways.
- Successful Rescue: Cells transfected with THBS1-overexpression plasmids showed significantly higher survival rates and restored signaling activity even when exposed to entrectinib.
Discussion and Future Work
The identification of THBS1 as a master regulator of entrectinib-induced neurotoxicity provides a clear molecular link to the drug's side effects. The conservation of this mechanism across rat, mouse, and human cells suggests a fundamental biological response.
However, a primary limitation is that this study was conducted entirely in vitro. While cell lines are excellent for identifying molecular pathways, they cannot fully replicate the complexity of a living brain. Future research must move into in vivo animal models to confirm if THBS1-based interventions can prevent neurological symptoms in a whole organism. Additionally, clinical studies are needed to determine if THBS1 levels in patients correlate with the severity of CNS side effects, potentially serving as a biomarker for toxicity risk.
Data Availability: Transcriptome sequencing data is deposited in the Sequence Read Archive (SRA) under accession number PRJNA1219491.
Summary updated